Industry Satellite Symposium
The evolution of systemic treatments for sarcomas (7mins)
Prof. Peter Reichardt reviews how treating rare sarcomas has evolved from the first successful chemotherapy 50 years ago to the breakthroughs with imatinib and other TKIs over the last 23 years.
Surgical approaches for the treatment of GIST and TGCT (9mins)
Dr Alessandro Gronchi focuses on treatments for localised GIST, including in metastatic disease, with the latest surgical and radiological approaches. He explains the two types of TGCT, nodular and diffuse, and how surgery is currently the only intervention commonly used, although medical treatments under investigation hold promise.
The changing treatment landscape of TGCT (9mins)
Prof. Hans Gelderblom outlines the impact of TGCT on patients and the multiple paths being explored in treating them. TGCT has a high impact on patients’ daily activities and can recur quickly after surgery. TKIs have been used off-label to medically treat patients with moderate success but current clinical trials focus on more specific inhibition of CSF1 signalling by TKIs or monoclonal antibodies.
The future of treatment optimisation for patients with advanced GIST (14mins)
Prof. Axel Le Cesne reviews how patient survival in advanced GIST has been extended with the development of the modern TKI treatment algorithm. Analysis of ctDNA to enable treating the right patients and monitoring secondary resistance, in parallel with a multitude of clinical trials of new and existing agents and combination treatments, will hopefully lead to improved outcomes.
Industry Satellite Symposium
An overview of the pathogenesis and initial treatment (18mins)
Dr Napolitano leads the audience on a journey from the earliest identification of the cells that lead to GIST and the background to the development of TKI therapies. He covers GIST subtypes, their features and repercussions on risk. Looking at TKI mechanisms he outlines the treatment pathways in advanced lines of therapy, with a focus on the impact of specific mutations.
What do we do after imatinib? (17mins)
Dr Watson outlines the advances made in the treatment of GIST over the last 20 years including a shift in the approaches to translational research that have led to the identification of mutations that drives new therapeutic research. As secondary mutations occur, different drugs are needed, and Dr Watson talks through the clinical evidence supporting the efficacy and safety of the current armamentarium of TKIs.
How would we like to see GIST being managed in the future? (24mins)
Dr Serrano talks about the role of ctDNA in GIST, its development as a clinical biomarker and how to implement liquid biopsy in clinical trials. Dr Serrano covers the evidence and benefits of identifying genomic targets, both for existing agents and those under investigation. ctDNA data from trials including INTRIGUE, INSIGHT (ripretinib vs sunitinib), and VOYAGER (avapritinib vs regorafenib), are discussed, with a focus on mutational landscapes and prediction of outcomes. Finally he outlines a hypothetical future with therapy choices attuned to the individual.
Industry Satellite Symposium
Emerging therapeutic strategies (27mins)
Prof. Sebastian Bauer explains what drives secondary imatinib resistance, exploring its clinical implications and correlates, and analyses key outcomes and lessons learned with ripretinib in the INTRIGUE trial, as we look towards the INSIGHT phase 3 open-label trial later this year.
The case for ripretinib (13mins)
Dr Charlotte Benson reviews recent progress in GIST therapy, leading to the development of ripretinib, outcomes in INVICTUS crossover patients, and in case studies which highlight the importance of individualising treatment with multi-disciplinary management to maximise clinical benefit.
Towards individualised medical treatment (13mins)
Prof. Sebastien Bauer on behalf and with the permission of Prof. Bruno Vincenzi explains the importance of individualised medical treatment in the era of TKI, with a multidisciplinary and multimodal approach critical to optimising outcomes in the treatment of patients with GIST.
Industry Satellite Symposium
Treatment landscape (19mins)
Prof. Axel Le Cesne reviews the different primary aetiologies of advanced GIST and how each has its own treatment approach before delving into how ripretinib and other tyrosine kinase inhibitors can benefit patients with secondary resistance to imatinib.
Stable disease and quality of life (13mins)
Prof. Antoine Italiano examines how avoiding disease progression in patients with advanced GIST thanks to the array of modern treatment regimens and their adaptation to each patient is leading to improved quality of life.
Managing patients with progressing GIST (23mins)
Prof. Peter Reichardt uses a combination of patient case studies and clinical trial data to show how determining progressive disease in a patient can be more complex than it seems at first glance and how to balance efficacy and tolerability for the benefit of the patient when navigating the subsequent lines of treatment.
Industry Satellite Symposium
When to operate (20 mins)
Prof. Alessandro Gronchi discusses the role of surgery and pharmacological therapy in patients with localised and metastatic GIST, showcasing data to support recommended management strategies.
Getting into the details (18 mins)
Dr Cesar Serrano examines the importance of elucidating the mutations involved in patients diagnosed with GIST.
Evolution of treatment (17 mins)
Prof. Axel Le Cesne reviews the impact of the growing number of treatment options for advanced GIST and discusses the key challenge of secondary resistance after imatinib.
Industry Satellite Symposium
Disease landscape (22 mins)
Prof. Peter Reichardt provides an overview of the GIST disease landscape and discusses clinical presentation and diagnosis, the impact of mutations, and currently recommended management strategies.
Treatment challenges (21 mins)
Prof. Sebastian Bauer reviews the guideline-recommended treatments for locally advanced/metastatic GIST and comments on the challenges faced in managing these patients.
The new toolbox for GIST (19 mins)
Prof. Jean-Yves Blay discusses the latest treatments for GIST (including mutation-selective therapies), their role in the management of patients with advanced disease, and the data supporting their use.
We use cookies that are strictly necessary to operate this website. We also use optional cookies to analyze and track your use of our website, and to give you the best possible user experience. By clicking on the “Reject All Cookies” button, you understand that strictly necessary cookies will continue to be deployed for the operation of this website. For more detailed information on our use of cookies on this website, please read our Cookies policy, which also explains how to customize your cookies settings.
Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
You have reached the GIST Hub website developed by Deciphera to provide you with information about Gastrointestinal Stromal Tumours (GIST).
Please click on the link appropriate for you
May 2024 | DCPH-P00927
You are now leaving GIST hub, Deciphera does not endorse or accept liability for sites controlled by third parties
